Buy Foundayo in the UK: Availability and How to Get It

Foundayo is the brand name for orforglipron, a weight management medicine licensed by the MHRA on 10 August 2026. It is taken as a tablet once a day. That single fact is why so many people started searching for it, and why much of what has been written since skips straight to buying and never explains what the medicine is.

This page does the opposite. It starts with the medicine, because what Foundayo does, what the trials measured, who it is licensed for and what taking it involves is what tells you whether trying to buy it is worth your time at all. Access comes at the end, where it belongs.

Key things to know

• Foundayo is the brand name for orforglipron, licensed in the UK on 10 August 2026.
• It is a once daily tablet, taken at any time of day, with no requirement to time it around food or water.
• It is licensed for weight loss and for weight maintenance in adults, alongside a reduced calorie diet and increased physical activity.
• It is also licensed for blood glucose control in adults with type 2 diabetes that is not adequately controlled.
• The eligibility threshold is a BMI of 30 or above, or 27 to 30 with a weight related health condition.
• In the phase 3 programme, average weight loss over 72 weeks ranged from around 7.5% to 11.2% across the dose groups studied, against around 2.1% on placebo.
• It is a prescription only medicine in the UK. It cannot be bought over a counter or from a general retailer.
• Approval and supply are separate things. UK availability is still being established.

What Foundayo actually is

Foundayo is a GLP-1 receptor agonist taken by mouth. GLP-1 is a hormone your gut releases after you eat. It tells the pancreas to release insulin, helps regulate blood sugar levels, slows how quickly the stomach empties, and signals to the brain that you have had enough. A GLP-1 receptor agonist switches on the same receptors that hormone uses, so the body responds as though more of it were present.

The practical result is that appetite signals change. This can help some people lose weight and support weight loss by reducing interest in food, helping them feel full sooner, and making portions they would previously have finished feel less appealing. It is not a fat burner and it does not block absorption. It works on the decision to eat.

Why Foundayo is a tablet when similar medicines are injections

Many established GLP-1 medicines are peptide-based. Peptides are broken down during digestion, which is one reason many GLP-1 treatments have traditionally been given by injection. Some oral peptide medicines need specific instructions about fasting, food and water to support absorption.

Orforglipron is different. It is a small-molecule, non-peptide GLP-1 receptor agonist, which allows it to be taken as a tablet. The UK product information states that Foundayo can be taken once daily at any time of day, with or without food.

Orforglipron is not a peptide. It is a small molecule, chemically closer to an ordinary tablet medicine than to a hormone. Digestion does not dismantle it in the same way, so it survives the stomach and is absorbed without any of that machinery, with an absorption rate of around 79% per dose. This difference also matters for oral medicines, because the licensed instructions carry no food or water restriction and no waiting period. You take it once a day, at whatever time suits you.

A tablet may be more convenient for someone who prefers to avoid injections, while a weekly injectable may suit someone who prefers less frequent dosing. The appropriate treatment depends on individual clinical circumstances and preference.

What Foundayo is licensed for in the UK

A licence is not general permission to use a medicine however you like. It states which patients, for which purpose, on what basis. Foundayo is a prescription weight loss treatment with two licensed uses in the UK.

Two details in that table are worth pausing on, and these licensed uses place it among UK weight loss treatments for eligible adults.

The first is that weight maintenance is named in the licence, not only weight loss. Weight maintenance is specifically included within the authorised weight-management indication, rather than the indication being limited to initial weight loss.

The second is the phrase "alongside a reduced calorie diet and increased physical activity". This is not a polite addition. It is part of what the medicine is licensed to do. The trial results were produced by people taking the medicine and changing how they ate and moved. The authorised use specifies that Foundayo should be used alongside a reduced-calorie diet and increased physical activity. These lifestyle measures therefore form part of the overall treatment approach.

What the trial evidence shows

The phase 3 programme ran over 72 weeks, which is around sixteen months. Average weight loss ranged from about 7.5% to about 11.2% depending on the dose group studied. The placebo group averaged around 2.1%. In separate studies for other prescription weight-loss medicines, Mounjaro reported average weight loss of 22.5% over 72 weeks, while Wegovy reported about 17% over 64 weeks, so these figures should be read as study-specific context rather than direct like-for-like comparisons.

Work those percentages out against your own body weight rather than reading them as abstractions. For someone at 100kg, the range across the dose groups corresponds to roughly 7.5kg to 11kg from starting body weight over sixteen months. Whether that represents meaningful weight loss for you is worth deciding before you start rather than at week twenty.

What the evidence does not show

Being straight about the gaps is part of reading evidence properly.

• The trials ran to 72 weeks. They do not tell you what happens at four years.
• There is no published head to head trial comparing Foundayo directly against established injectable weight management treatments, including weight loss injections. No published head-to-head clinical trials directly compare Foundayo with those options. Comparing separate trials with different participants, entry criteria and study designs is not the same as testing two medicines against each other.
• Evidence on switching to orforglipron is now emerging. The ATTAIN-MAINTAIN trial studied orforglipron in people who had previously completed treatment with tirzepatide or semaglutide, but this evidence should not be interpreted as establishing that switching is appropriate for every patient.

The MHRA has said it will keep the safety and effectiveness of this medicine under close review, which is standard for a newly licensed treatment and a reason to expect the guidance around it to develop. Future interpretation may also be influenced by the National Institute for Health and Care Excellence, but current conclusions still depend mainly on the limits of the published clinical trials.

Who can be supplied

Eligibility is not a formality a service waves you through. It decides whether you can be supplied at all.

Working out your BMI

BMI, or body mass index, is calculated by dividing your weight in kilograms by the square of your height in metres. For example, someone who is 1.70m tall and weighs 87kg has a BMI of around 30.1, while the same height at 80kg corresponds to a BMI of approximately 27.7.

BMI is a blunt instrument. It does not distinguish muscle from fat, so a very muscular person can have a high BMI without carrying excess fat. BMI is only one part of a clinical assessment. The Foundayo weight-management indication uses the BMI thresholds specified in the UK authorisation, while the prescriber will also consider your health conditions, medicines and overall clinical circumstances.

When it is not suitable

Foundayo is not appropriate for everyone who meets the BMI criteria. The prescriber will consider your medical history, current medicines and other circumstances before deciding whether treatment is suitable.

There are specific contraindications and warnings in the product information, including a known hypersensitivity to orforglipron or its ingredients. Foundayo is also not recommended for people with NYHA class IV congestive heart failure. There are additional precautions concerning conditions such as pancreatitis, gallbladder disease, severe gastrointestinal disease and certain thyroid conditions.

Pregnancy and breastfeeding also require specific consideration: Foundayo should not be used during pregnancy or breastfeeding according to the current patient information.

What taking Foundayo involves

You take Foundayo once a day. There is no injection technique to learn, no refrigeration to organise, no needles to dispose of and no window of time you have to hit. Attaching this daily weight loss tablet to something you already do daily helps, because daily medicines are forgotten more often than weekly ones.

Treatment starts at a lower starting dose and increases in steps. That gradual increase lets the digestive system adjust, helping to reduce common side effects like nausea or severe stomach pain. Your prescriber sets the schedule for Foundayo tablets, increasing to the maximum Foundayo dose they consider appropriate rather than moving straight to the highest dose, and no schedule for the Foundayo pill should be published anywhere outside your own prescription.

Gradual dose escalation is used to improve tolerability, particularly because gastrointestinal side effects are common during treatment.

Missed doses

If you miss a dose of Foundayo, take it as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip the missed dose and take your next dose on the usual day.

Do not take two doses on the same day to make up for a missed dose. If you are unsure what to do, check the patient information leaflet or speak to your pharmacist or prescriber.

Side effects and what to expect

Digestive side effects are the common ones: nausea, headaches, vomiting, diarrhoea, constipation, indigestion and abdominal discomfort. They tend to appear when treatment starts and after each dose increases, and to ease as the body adjusts.

Constipation and diarrhoea are both commonly reported and can be more noticeable when treatment begins or after a dose increase. People with type 2 diabetes who use other glucose-lowering medicines may need clinical advice if they notice symptoms of low blood sugar.

Some effects are not part of adjusting. Severe, persistent abdominal pain, particularly pain going through to the back with vomiting, needs urgent medical assessment, as does any sign of an allergic reaction. Suspected side effects can be reported through the MHRA Yellow Card scheme, which is how safety signals for new medicines are picked up.

Monitoring, review and stopping

A legitimate weight management service does not hand over a medicine and disappear. Expect a review covering how you are tolerating treatment, what your weight is doing, whether side effects are manageable, whether continuing makes clinical sense, and what support is in place throughout your weight loss journey.

Stopping deserves more thought than it gets. National quality standards on managing overweight and obesity, published on 5 August 2025, recommend support for at least a year after stopping a weight management medicine: regular feedback, help building routines that hold without it, and an agreed plan if weight starts to return.

Where UK availability stands and how to get it

Approval and supply are separate stages. MHRA licensing is a regulatory judgement that a medicine meets the standards for quality, safety and effectiveness. Getting it into pharmacies is a manufacturing and distribution process on its own timetable. Foundayo has been authorised in the UK by the MHRA. Authorisation and pharmacy supply are separate matters, so actual availability may vary between providers.

Foundayo is a prescription only medicine. That means there is one lawful route to it in the UK, and it looks like this:

1. Complete an online consultation with UK registered prescribers, covering your measurements, medical history and current medicines.
2. A prescriber reviews it and decides whether the medicine is clinically appropriate for you. This is a decision, not a confirmation step, and private prescribers may have different criteria for Foundayo within the same clinical and legal requirements.
3. If approved, a prescription is issued and dispensed by a GPhC registered pharmacy.
4. The medicine is dispensed and delivered to you with its patient information leaflet.
5. You are reviewed during treatment rather than left to manage alone.

Anything that skips the assessment is not this route. Be cautious about services that offer treatment without a genuine clinical assessment or prescription, or that use urgency to pressure you into ordering. You can check whether a pharmacy is registered through the GPhC register, and a medicine's UK licensing status through the Medicines and Healthcare Products Regulatory Agency before checking the MHRA.

Recognising genuine supply

When your medicine arrives, check that the product name, strength and dispensing label match what was prescribed. The packaging should be intact and accompanied by the appropriate patient information leaflet. Check the batch details and expiry date as well.

If anything appears unusual, for example, the medicine or strength does not match your prescription, the packaging is damaged, or the expected information is missing, contact the dispensing pharmacy before taking the medicine.

Medical Disclaimer

This article is general information about prescription only medicine and is not medical advice. It is not a recommendation to take any treatment, and it does not replace an assessment by a qualified healthcare professional who knows your medical history. Foundayo should only be used under the supervision of an appropriately qualified prescriber. Results vary between individuals.

Always read the patient information leaflet supplied with your medicine and follow the instructions your prescriber gives you. If you develop severe or persistent abdominal pain, ongoing vomiting or signs of an allergic reaction, seek urgent medical attention. Suspected side effects can be reported through the MHRA Yellow Card scheme.